Business Wire

FourKites Appoints New President Rocky Subramanian to Accelerate Global Expansion

6.4.2023 11:08:00 EEST | Business Wire | Press release

Share

Leading supply chain visibility company FourKites today announces the appointment of Rocky Subramanian as President, effective immediately. Widely respected as a trusted advisor to leaders executing complex digital transformation at organisations of all sizes, Subramanian will work alongside CEO Mathew Elenjickal to drive the company's strategy, growth and customer success globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005293/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites announces the appointment of Rocky Subramanian as President (Photo: Business Wire)

“As our new President, Rocky will be key to taking FourKites to the next level,” said Elenjickal. “He has a proven track record in delivering big wins for customers, building world-class teams, championing workplace diversity and culture, scaling processes and growing thriving partner ecosystems. Just as important, he passionately shares my belief that better supply chains make the world a better place. I’m honoured to welcome him to our executive team as we accelerate FourKites’ growth trajectory.”

Subramanian was most recently Executive Vice President and CRO at Ceridian (NYSE:CDAY), where he helped the company grow to over $1.2B in revenue, added some of the biggest global brands as customers, and transformed the revenue organisation. He previously served as Senior Vice President and Managing Director of one of SAP’s (NYSE:SAP) largest market units — with responsibilities spanning sales, go-to-market strategy, operations and services for the entire enterprise software portfolio — which he grew to over $1.8B. Prior to SAP, Subramanian served in various roles at Oracle/PeopleSoft (NYSE:ORCL), Renaissance and NCS Pearson. He also advises as a volunteer mentor, and supports organisations with missions focused on education accessibility and eradicating hunger.

“From the beginning, I have been inspired by FourKites’ vision. It goes far beyond visibility; FourKites is helping companies lower costs, improve customer satisfaction, enhance workplace productivity and achieve their sustainability goals. It’s helping get food, medication and critical supplies to people who need them — faster and more reliably than ever before,” said Subramanian. “Paired with the company’s world-class products, pace of innovation, rapid deployment, thriving partner ecosystem and the scale at which we can help our customers, the potential for FourKites’ global impact is limitless. I’m excited and proud to join Matt and the entire FourKites team on this mission.”

Subramanian’s appointment comes on the heels of significant momentum for FourKites. In 2022, the company realised 70% growth in new customers, with more than 1,200 of the world’s most recognised brands — including 50% of the Fortune 500 — now using FourKites to track more than 3 million shipments around the world every day. In addition to strategic investments in 2021 from industry heavyweights Qualcomm Ventures, LLC, Volvo Group Venture Capital AB and Zebra Technologies, over the past year, FourKites inked strategic partnerships with a number of industry titans to continue executing on its bold vision to provide visibility everywhere. These companies include Mitsui & Co., Ltd., Quiet Platforms, Sony, Microsoft and Narvar. The real-time supply chain visibility pioneer was also recognised for its industry leadership and ongoing innovation by Gartner, SupplyChainBrain, Blue Yonder, Builtin Chicago, Manhattan Associates and Food Shippers of America.

FourKites continues to attract top talent to its senior leadership team as it scales its global operations and reinforces its focus on customer success. In addition to Subramanian, the company recently announced the appointment of Rebecca Nerad as Vice President of Global Customer Success, and Natalie Wolf, Vice President of Customer Operations and Strategy. Nerad has over 20 years in the supply chain industry, having held senior customer success roles at e2open, i2 Technologies, JDA Software and Bristlecone, while Wolf has held senior customer experience roles at Anaplan and Celonis.

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
FourKites European PR Director
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye